Form 4: CRISPR Therapeutics CFO Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Raju Prasad, CFO of CRISPR Therapeutics, was granted stock options for 36,168 common shares and 25,000 restricted stock units on March 20, 2024.
Summary
- On March 20, 2024, Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics, received stock options and restricted stock units.
- The stock options grant was for 36,168 common shares with an exercise price of $72.94.
- These options vest in 48 equal monthly installments starting April 20, 2024.
- Prasad also received 25,000 restricted stock units, each representing a contingent right to receive one share of CRSP Common Shares.
- One quarter of the restricted stock units will vest annually on March 20, from 2025 to 2028.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive signal.
Positives
- The grant of stock options and restricted stock units aligns the CFO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Granting stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical also use stock options and RSUs to incentivize their executives.
- The vesting schedules are typical, with monthly vesting for options and annual or quarterly vesting for RSUs over a 3-4 year period.
Stakeholder Impact
- The grant of equity to the CFO aligns his interests with those of shareholders, potentially leading to better decision-making.
- Employees may view this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/20/2024 | Date of the transaction: grant of stock options and restricted stock units. |
| 04/20/2024 | First vesting date for the stock options. |
| 03/20/2025 | First vesting date for the restricted stock units (one quarter). |
| 03/20/2026 | Second vesting date for the restricted stock units (one quarter). |
| 03/20/2027 | Third vesting date for the restricted stock units (one quarter). |
| 03/20/2028 | Final vesting date for the restricted stock units (one quarter). |
| 03/20/2034 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.